Clinical trials
Renal Cancer clinical trials
Below are recruiting renal cancer clinical trials, each written for real people, not researchers. We’re tracking 252 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06934057RecruitingPhase 4
Cabozantinib and Nivolumab for older adults with kidney cancer
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
AngersAges 70 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT06145139Enrolling by invitation
Liquid biopsy for kidney cancer: tracking tumor DNA after surgery
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
Aarhus NAges 18 years+ - NCT04605146Recruiting
Telemonitoring to manage side effects from immunotherapy
This trial tests whether using home digital monitoring (telemonitoring) can help people with melanoma, lung, or kidney (renal) cancer manage side effects while on immunotherapy. It may help catch side effects earlier and support you during treatment with nivolumab plus ipilimumab or nivolumab alone.
BronAges 18 years+ - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT06432036RecruitingPhase 1/Phase 2
Y90 Radioembolization for Early Kidney Cancer
This trial tests a treatment called Y90 radioembolization for people with early-stage kidney cancer who cannot have surgery or ablation. Tiny radioactive beads are delivered through a catheter to the tumor's blood supply to destroy it from the inside.
Los Angeles, CaliforniaAges 18 years+ - NCT03755739RecruitingPhase 2/Phase 3
Checkpoint cancer drug given into or near tumors
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
Guanzhou, GuangdongAges 18 years+ - NCT04197414Recruiting
Urology DNA registry to personalize cancer care
This study builds a urology cancer “DNA registry” by analyzing circulating tumor DNA found in the blood. Your information and permission help researchers better personalize treatment for cancers like prostate, kidney, bladder, and ureter cancer.
SeoulAges 20 years+ - NCT04625556Recruiting
Urology cancer registry study using body microbiome data
This study builds a patient registry for prostate, kidney, bladder, and ureter cancers by analyzing your body’s microbiome (the microbes living in/ on the body). It may help doctors personalize care in the future, and your participation mainly involves allowing your medical and related information to be used for research.
SeoulAges 20 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT04623502Recruiting
Study of kidney and bladder cancer metabolism during surgery
This study looks at how kidney and bladder (urothelial) tumors use fuel by taking samples during surgery or biopsy. It may help researchers learn what drives these cancers and guide better future treatments.
Dallas, TexasAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05060783Recruiting
Liquid blood test to help detect kidney cancer
This study tests whether a “liquid biopsy” blood test can help detect kidney cancer when a CT scan looks suspicious but does not show cancer. It may help avoid unnecessary procedures or catch cancer patterns earlier, but it will depend on the type of kidney tumor and your situation.
RoskildeAges 18 years+ - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT07088536Recruiting
Returning to work after urology surgery
This study looks at how urology surgeries, like removing a kidney or treating kidney stones, affect patients' ability to return to work. It will help doctors understand the challenges patients face when going back to their jobs.
Krakow, MalopolskaAges 18 years+ - NCT06281678RecruitingPhase 2
Study of IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
San Francisco, CaliforniaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06088134Recruiting
Predicting survival after kidney cancer surgery with CT scans
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT07307157Enrolling by invitation
AI vs. pathologists: Which diagnoses cancer better?
This study tests a new AI system called COSMO against pathologists to see which is better at diagnosing cancer from digital slides. If you are an experienced pathologist, you will review slides independently, and your results will be compared with the AI's.
Boston, MassachusettsAges Any age - NCT07141225Recruiting
Testing no-clamp, no-suture robot kidney surgery
This study is testing a special technique in robot-assisted kidney surgery where the blood supply to the kidney is not clamped and the tumor is removed without sutures. It may reduce damage to healthy kidney tissue and speed recovery.
Nanjing, JiangsuAges 18–80
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cancer?
- Yes. Clin2 currently lists 252 recruiting renal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.